Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 19/20 | 0.54 |
| ▸ | EGFR | P00533 | 13/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | FECH | P22830 | 1/20 | 0.48 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.48 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21561494 | 0.91 | ERBB2 (0.53) | ERBB2EGFRAAK1 | |
| SCHEMBL21561484 | 0.90 | EGFR (0.67) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL21561466 | 0.90 | ERBB2 (0.56) | ERBB2EGFRAAK1LCKKDR | |
| SCHEMBL21561475 | 0.87 | EGFR (0.54) | ERBB2EGFRAAK1NQO2FECH | |
| SCHEMBL21561477 | 0.87 | EGFR (0.54) | ERBB2EGFRAAK1LCKNQO2 | |
| SCHEMBL21561485 | 0.87 | ERBB2 (0.53) | ERBB2EGFRAAK1NQO2FECH | |
| SCHEMBL21561482 | 0.87 | ERBB2 (0.52) | ERBB2EGFRAAK1NQO2FECH | |
| SCHEMBL21561498 | 0.86 | ERBB2 (0.51) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL21561496 | 0.86 | AAK1 (0.66) | ERBB2EGFRAAK1 | |
| SCHEMBL21561471 | 0.85 | ERBB2 (0.51) | ERBB2EGFRAAK1LCKNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2024-07-09 | — | — | US | disclosed |
| EP-3792263-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC (CN) | 2023-03-01 | — | — | EP | disclosed |
| US-20210323979-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-10-21 | — | — | US | disclosed |
| EP-3792263-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | Medshine Discovery Inc. (CN) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019214651-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885AAK1 458/4885 |
| US-20210323979-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885AAK1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.